severe pneumonia
Conditions
Interventions
Rimazolam benzenesulfonate group:Rimazolam benzenesulfonate loading dose: 0.2mg/kg, 1min slow sedation, maintenance dose: 0.25-1 mg/kg/h
maintenance of RASS score -2-0, if the depth of sedation is insufficient, add cyclobenzaprine 0.06-0.8mg/kg/h
Midazolam group:Midazolam 0.02-0.1 mg / kg / h, maintain RASS score-2 ~ 0 points, if the depth of sedation is insufficient, add propofol 0.06-0.8 mg / kg / h.
Sponsors
Anhui Chest Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Patients aged >=18 years; 2. Meet the diagnostic criteria for severe pneumonia: conform to the SCAP diagnostic criteria of the 2007 IDSA/ATS guidelines: meet 1 major diagnostic criterion or >=3 minor diagnostic criteria; Secondary diagnostic criteria included: (1) respiratory rate > 30 breaths/min; (2) oxygenation index (Arterial oxygen partial pressure/Inhaled oxygen concentration, PaO2/FiO2) 20 mg/dL; (6) white blood cell count < 4 × 10^9/L; (7) platelet count < 100 × 10^9/L; (8) central body temperature < 36°C; (9) hypotension (systolic blood pressure < 90 mmHg, requiring aggressive fluid resuscitation); 3. Obtaining informed consent from the patient or family.
Exclusion criteria
Exclusion criteria: 1) Age <18 years; 2) Women who are pregnant or are breastfeeding; 3) Hypersensitivity to remazolam or midazolam; (4) Patients with autoimmune diseases or long-term use of immunosuppressive drugs; (5) Patients with a history of severe cardiac arrhythmia; 6) Those whose medical condition does not allow the use of remazolam or midazolam sedation therapy; 7) Patients who refuse to participate in this study by themselves or their families; 8) Any other condition that the investigator considers inappropriate for enrollment; 9) Any condition that prevents the correct assessment of cognitive functioning, such as speech and sensory disorders or psychiatric disorders (speech difficulties or psycho-organic dysfunction); 10) Patients with myasthenia gravis; 11) Patients with a history of alcohol or drug abuse.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Rass score; | — |
Secondary
| Measure | Time frame |
|---|---|
| blood gas analysis;BBlood routine(CRP);Interleukin 6, IL-6;Absolute lymphocyte count;Sofa score;Mechanical ventilation; | — |
Countries
China
Contacts
Public ContactHaobo Kong
Anhui Chest Hospital
Outcome results
None listed